Cerus Websites

INTERCEPT® Fibrinogen Complex

Ready When You Are.
INTERCEPT Fibrinogen Complex is a pathogen reduced, fibrinogen enriched, blood component for transfusion providing you with an immediate source* of key factors known to be important in effective hemostasis.

Breakthrough Device for Treating Uncontrolled Bleeding

The ready-to-use Fibrinogen Complex* approved specifically for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

 

  • Pathogen Reduced Cryoprecipitated Fibrinogen Complex (Fibrinogen Complex) is prepared from the INTERCEPT® Blood System for Cryoprecipitation.
  • Immediate, enriched source of key factors in effective hemostasis1-3
      • Fibrinogen
      • Factor XIII
      • von Willebrand Factor (vWF)
      • Other vital clotting proteins

Transfuse With The First Blood Products*

The INTERCEPT Fibrinogen Complex is approved for empirical use.

Improve Order-to-Transfusion Times

TRANSFUSION READY

  • Thawed in advance
  • Ready to deploy with first blood products
  • No additional labelling or preparation required

CONVENIENT DOSING

  • Single-use hemostatic doses
  • Pre-pooled high doses available**

MINIMIZED WASTE

  • 5-day post-thaw shelf life
  • Return to inventory if not transfused
  • Broad spectrum transfusion transmitted infection (TTI) risk reduction

INTERCEPT Pathogen Reduced Cryoprecipitated Fibrinogen Complex is indicated for6:

  • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
  • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
  • Second-line therapy for von Willebrand disease (vWD).
  • Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: INTERCEPT Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII

ORDER TODAY

INTERCEPT Fibrinogen Complex is now FDA approved for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency.

Become a Customer

You May Also Be Interested In

PATHOGEN REDUCTION: Be Ready. Reduce the risk of transfusion transmitted infections by using blood products treated with the INTERCEPT Blood System Pathogen Reduction System.

READ MORE

DOSAGE: Hemorrhage control requires all hands on deck. Pre-pooled INTERCEPT Fibrinogen Complex facilitates transfusion of high doses of fibrinogen from a single container.

READ MORE

ONBOARDING: Implement once, streamlined ordering after.

READ MORE

* INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
**Pooling facilitates transfusion of high doses of fibrinogen from a single container. Fibrinogen content of Fibrinogen Complex depends on donor plasma fibrinogen levels.

References
1. Levy JH, Welsby I, et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014;54(5):1389-1405; quiz 1388. 2. Schroeder V, Kohler HP. Factor XIII: Structure and Function. Semin Thromb Hemost 2016;42(4):422-428. 3. Peyvandi, F. Diagnosis and management of patients with von Willebrand’s disease in Italy: an Expert Meeting Report. Blood Transfus 2018;16(4):326-328. 4. Holcomb JB, Fox EE, Zhang X, et al. Cryoprecipitate Use in the Prospective Observational Multicenter Major Trauma Transfusion study (PROMMTT). The journal of trauma and acute care surgery 2013;75:S31-S9. 5. AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2017. 6. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex [Package Insert]. Concord, CA. Cerus Corporation. January 20, 2021.